Literature DB >> 22308357

Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.

Hiroaki Shime1, Misako Matsumoto, Hiroyuki Oshiumi, Shinya Tanaka, Akio Nakane, Yoichiro Iwakura, Hideaki Tahara, Norimitsu Inoue, Tsukasa Seya.   

Abstract

Smoldering inflammation often increases the risk of progression for malignant tumors and simultaneously matures myeloid dendritic cells (mDCs) for cell-mediated immunity. PolyI:C, a dsRNA analog, is reported to induce inflammation and potent antitumor immune responses via the Toll-like receptor 3/Toll-IL-1 receptor domain-containing adaptor molecule 1 (TICAM-1) and melanoma differentiation-associated protein 5/IFN-β promoter stimulator 1 (IPS-1) pathways in mDCs to drive activation of natural killer cells and cytotoxic T lymphocytes. Here, we found that i.p. or s.c. injection of polyI:C to Lewis lung carcinoma tumor-implant mice resulted in tumor regression by converting tumor-supporting macrophages (Mfs) to tumor suppressors. F4/80(+)/Gr1(-) Mfs infiltrating the tumor respond to polyI:C to rapidly produce inflammatory cytokines and thereafter accelerate M1 polarization. TNF-α was increased within 1 h in both tumor and serum upon polyI:C injection into tumor-bearing mice, followed by tumor hemorrhagic necrosis and growth suppression. These tumor responses were abolished in TNF-α(-/-) mice. Furthermore, F4/80(+) Mfs in tumors extracted from polyI:C-injected mice sustained Lewis lung carcinoma cytotoxic activity, and this activity was partly abrogated by anti-TNF-α Ab. Genes for supporting M1 polarization were subsequently up-regulated in the tumor-infiltrating Mfs. These responses were completely abrogated in TICAM-1(-/-) mice, and unaffected in myeloid differentiation factor 88(-/-) and IPS-1(-/-) mice. Thus, the TICAM-1 pathway is not only important to mature mDCs for cross-priming and natural killer cell activation in the induction of tumor immunity, but also critically engaged in tumor suppression by converting tumor-supporting Mfs to those with tumoricidal properties.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22308357      PMCID: PMC3277567          DOI: 10.1073/pnas.1113099109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

Review 1.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).

Authors:  Subhra K Biswas; Lisa Gangi; Saki Paul; Tiziana Schioppa; Alessandra Saccani; Marina Sironi; Barbara Bottazzi; Andrea Doni; Bronte Vincenzo; Fabio Pasqualini; Luca Vago; Manuela Nebuloni; Alberto Mantovani; Antonio Sica
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

Review 4.  New vistas on macrophage differentiation and activation.

Authors:  Alberto Mantovani; Antonio Sica; Massimo Locati
Journal:  Eur J Immunol       Date:  2007-01       Impact factor: 5.532

Review 5.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

6.  IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses.

Authors:  Thomas Krausgruber; Katrina Blazek; Tim Smallie; Saba Alzabin; Helen Lockstone; Natasha Sahgal; Tracy Hussell; Marc Feldmann; Irina A Udalova
Journal:  Nat Immunol       Date:  2011-01-16       Impact factor: 25.606

7.  Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice.

Authors:  Marta Torroella-Kouri; Xiaojing Ma; Giselle Perry; Milena Ivanova; Pedro J Cejas; Jennifer L Owen; Vijaya Iragavarapu-Charyulu; Diana M Lopez
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

8.  Raftlin is involved in the nucleocapture complex to induce poly(I:C)-mediated TLR3 activation.

Authors:  Ayako Watanabe; Megumi Tatematsu; Kazuko Saeki; Sachiko Shibata; Hiroaki Shime; Akihiko Yoshimura; Chikashi Obuse; Tsukasa Seya; Misako Matsumoto
Journal:  J Biol Chem       Date:  2011-01-25       Impact factor: 5.157

9.  Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.

Authors:  J E Talmadge; J Adams; H Phillips; M Collins; B Lenz; M Schneider; E Schlick; R Ruffmann; R H Wiltrout; M A Chirigos
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

10.  Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88.

Authors:  Seth Rakoff-Nahoum; Ruslan Medzhitov
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

View more
  94 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  Medicinal facilities to B16F10 melanoma cells for distant metastasis control with a supramolecular complex by DEAE-dextran-MMA copolymer/paclitaxel.

Authors:  Yuki Eshita; Rui-Cheng Ji; Masayasu Onishi; Takashi Kobayashi; Masaaki Mizuno; Jun Yoshida; Naoji Kubota; Yasuhiko Onishi
Journal:  Drug Deliv Transl Res       Date:  2015-02       Impact factor: 4.617

3.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

4.  Association between Toll-like receptor 3 polymorphisms and cancer risk: a meta-analysis.

Authors:  Daye Cheng; Yiwen Hao; Wenling Zhou; Yiran Ma
Journal:  Tumour Biol       Date:  2014-05-13

5.  Vaccine-induced myeloid cell population dampens protective immunity to SIV.

Authors:  Yongjun Sui; Alison Hogg; Yichuan Wang; Blake Frey; Huifeng Yu; Zheng Xia; David Venzon; Katherine McKinnon; Jeremy Smedley; Mercy Gathuka; Dennis Klinman; Brandon F Keele; Sol Langermann; Linda Liu; Genoveffa Franchini; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

6.  Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage.

Authors:  Hiromi Takaki; Hiroaki Shime; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

7.  Coactivation of Estrogen Receptor and IKKβ Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer.

Authors:  Lamiaa El-Shennawy; Oleksii Dubrovskyi; Irida Kastrati; Jeanne M Danes; Yiqun Zhang; Herbert E Whiteley; Chad J Creighton; Jonna Frasor
Journal:  Cancer Res       Date:  2017-12-11       Impact factor: 12.701

Review 8.  Development and translation of novel therapeutics targeting tumor-associated macrophages.

Authors:  David Kosoff; Joshua M Lang
Journal:  Urol Oncol       Date:  2018-11-17       Impact factor: 3.498

9.  Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.

Authors:  Masahiro Azuma; Yohei Takeda; Hiroko Nakajima; Haruo Sugiyama; Takashi Ebihara; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

10.  Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad phosphorylation.

Authors:  Dain Son; Yi Rang Na; Eung-Soo Hwang; Seung Hyeok Seok
Journal:  J Biol Chem       Date:  2014-01-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.